Chugai Seiyaku Kabushiki Kaisha

Basilea Pharmaceutica Ag

F. Hoffmann-La Roche Ag

Basilea Pharmaceutica Ag, a Swiss Company

Tadakatsu Hayase

Nobuo Shimma

Isao Umeda

Jun Ohwada

Masao Tsukazaki

Hiroshi Fukuda

Masahiro Sakaitani

Nobuhiro Oikawa

Eisaku Mizuguchi

Hiroki Nishii

Lisha Wang

Susumu Komiyama

Takuo Tsukuda

Masayuki Matsushita

Yoshito Nakanishi

Hirosato Ebiike

Masayuki Ohmori

WeiLi Zhao

Ikumi Hyodo

Masami Kochi

Toshikazu Yamazaki

Naoki Taka

Toshiyuki Mio

Kyoko Takami

Kenichi Kawasaki

Takeshi Murata

Kiyoshi Hasegawa

Yoshiaki Isshiki

Fumio Watanabe

Kihito Hada

Masami Kohchi

Hiroshi Koyano

Ryoichi Saitoh

Atsushi Suda

Miyako Masubuchi

Shigeyasu Ichihara

Masayuki Sudoh

Naomi Ono

Ken-Ichi Kawasaki

Toshiya Sakai

Pingli Liu

Weili Zhao

A method for treating cancer that includes administering a pharmaceutically effective amount of a composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof. In the formula, A represents a 5- to 10-membered heteroaryl group, or a Caryl group; Rand Rindependently represent H, OH, X, CN, NO, a Chaloalkyl group, a Calkyl group, or the like &#x3c;Rand Rtogether form a (substituted) 3- to 10-membered heterocyclyl group or a (substituted) 5- to 10-membered heteroaryl group&#x3e;; Rrepresents H, a Calkyl group, a Caryl group, a Calkyl group, or a Chaloalkyl group; and Rrepresents H, X, a Calkyl group, a Chaloalkyl group, OH, CN, NO, or the like. 

Aminopyrazole derivative

A compound represented by formula (I) or a pharmacologically acceptable salt thereof, which can inhibit a fibroblast growth factor receptor (FGFR) family kinase in cancer tissues. (In the formula, A represents a 5- to 10-membered heteroaryl group, or a Caryl group; Rand Rindependently represent H, OH, X, CN, NO, a Chaloalkyl group, a Calkyl group, or the like &#x3c;Rand Rtogether form a (substituted) 3- to 10-membered heterocyclyl group or a (substituted) 5- to 10-membered heteroaryl group&#x3e;; Rrepresents H, a Calkyl group, a Caryl group, a Calkyl group, or a Chaloalkyl group; and Rrepresents H, X, a Calkyl group, a Chaloalkyl group, OH, CN, NO, or the like.) 

The present invention provides a novel class of compounds that have the activity of inhibiting HSP90 enzyme and are useful as anti-cancer agents or such, and compounds that are useful as synthetic intermediates thereof. Specifically, the present invention provides compounds represented by the following formula (1), and pharmaceutically acceptable salts thereof: wherein X, R, R, R, R, R, R, R, L, L, and Lare as defined in the specification.

Macrocyclic compound

N-substituted carbamoyloxyalkyl-azolium derivatives which have antifungal activity and are useful for the treatment of fungal diseases.

N-substituted carbamoyloxyalkyl-azolium derivatives

The object of the present invention is to provide a compound useful for the prevention and treatment of viral infectious diseases, and particularly liver diseases caused by HCV infection due to its having a high degree of replication inhibitory activity against HCV, its production method, an intermediate compound useful for its production and a pharmaceutical composition containing these compounds, and the present invention relates to a compound represented by the formula (I): 

Compound having anti-HCV activity and process for producing the same

N-substituted carbamoyloxyalkyl-azolium derivatives Which have antifungal activity and are useful for the treatment of fungal diseases.

N-phenyl substituted carbamoyloxyalkyl-azolium derivatives

Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives

Azoles for treatment of fungal infections

Growing community of inventors

Kanagawa, Japan

Tadakatsu Hayase